Please assess the completion status of the following clinical trial:

Trial Title: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent in accordance with federal, local, and institutional guidelines.~2. Age ≥ 18 years at the time of signing informed consent.~3. Patients must have previously received including proteasome inhibitors (PI) (i.e., lenalidomide) and immunomodulatory drugs (i.e., bortezomib) and were refractory to both drugs.~4. Any clinically significant non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #17) that patients experienced from treatments in previous clinical studies must have resolved to Grade ≤ 2 by Cycle 1 Day 1.~5. Adequate hepatic function within 21 days prior to Cycle 1 Day 1: total bilirubin \< 2x upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3x ULN), AST \< 2.5x ULN and ALT \< 2.5x ULN.~6. Adequate renal function within 21 days prior to Cycle 1 Day 1: estimated creatinine clearance of ≥ 20 mL/min, calculated using the formula of cockroft and gault.~7. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.~8. Measurable MM based on IMWG guidelines.~9. Adequate hematopoietic function within 21 days prior to Cycle 1 Day 1 (See Exclusion Criterion #20 for transfusion washout periods for RBCs and platelets):~   1. Hemoglobin level ≥ 8.5 g/dL~  2. ANC ≥ 1000/mm\^3~  3. Platelet count ≥ 75,000/mm\^3 (patients in whom \< 50% of bone marrow nucleated cells are plasma cells) or ≥ 50,000/mm\^3 (patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells. \[Platelet transfusions \< 1 week prior to Cycle 1 Day 1 are prohibited (see below).\]~10. Female subjects of child-bearing potential must have both of the following:~    1. Agree to the use of two study physician-approved contraceptive methods simultaneously, or practice complete abstinence starting at the time of ICF signature, while on study medication, and 3 months following the last dose of study drug.~   2. Have negative serum pregnancy test result at screening.~Exclusion Criteria:~* The presence of any of the following will exclude a subject from enrollment:~  1. Active smoldering MM.~ 2. Active plasma cell leukemia.~ 3. Documented systemic amyloid light chain amyloidosis.~ 4. Active central nervous system (CNS) MM.~ 5. Pregnancy or breastfeeding.~ 6. Chemotherapy ≤ 4 week, radiation and immunotherapy ≤ 4 weeks prior to Cycle 1 Day 1, and radio-immunotherapy 6 weeks prior to Cycle 1 Day 1.~ 7. Active graft vs. host disease (after allogeneic stem cell transplantation) at Cycle 1 Day 1~ 8. Life expectancy of \< 4 months.~ 9. Major surgery within four weeks prior to Cycle 1 Day 1.~ 10. Active, unstable cardiovascular function:~      1. Symptomatic ischemia, or~     2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or~     3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, or~     4. Myocardial infarction (MI) within 3 months prior to Cycle 1 Day 1.~ 11. Prior exposure to a SINE compound, including ATG-010.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATG-010 + Dexamethasone (Type: EXPERIMENTAL): Open-label ATG-010 80mg plus Dexamethasone 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).